Menu

Insights

Home » Insights » Insights Intercept Blood System
Regulations 08/08/2018

Pathogen Inactivation, towards becoming the standard of care in Germany

As of January 1, 2018, specific reimbursement for pathogen inactivated platelets is now available in Germany.

Cerus 08/08/2018

Madrid adopts INTERCEPT

On October 30, 2017 Cerus Corp. announced that it has entered into a two-year supply contract with Centro de Transfusion de la Comunidad de Madrid (CTCM) for the INTERCEPTTM Blood System for platelets.

Cerus 08/08/2018

EFS adopts INTERCEPT

The French Ministry of Health decided late 2016 that platelet pathogen inactivation should be deployed throughout the entire French territory for the control of bacterial infections transmitted by transfusion, following the recommendations of the National Agency for the Safety of Medicines and Health Products (ANSM).

Cerus 06/08/2018

Let us do something about it!

In 1982 was an epidemic of HIV in San Francisco. 300 patients acquired HIV infections from blood transfusions. The patients did not blame the hospital, but simply asked “Do something about it”. This request became the personal motivation of M.D. Larry Corash to found Cerus.

Economics 06/07/2018

The economics of Double Dose Buffy Coat Platelets

For blood centres seeking a cost-effective way to implement INTERCEPTTM pathogen inactivation, double dose buffy coat platelet production may offer a solution.

What is a double dose buffy coat platelet unit?

A platelet concentrate with sufficient platelet count to result in 2 therapeutic doses after pathogen inactivation with the INTERCEPT Blood System.

The double dose buffy coat platelet...